Rodney Rohde, PhD, MS, SM(ASCP)CM, shares his approach to initiating conversations around COVID-19 vaccination to patients and family members, highlighting the safety of administering multiple vaccines at during 1 visit.
Click through this short slide show for highlights of current Centers for Disease Control and Prevention recommendations for vaccination against COVID-19 that are discussed in the video. A text summary of the video appears below that.
This is a synopsis/summary of a panel discussion involving Tina Q. Tan, MD, and Rodney Rohde, PhD, MS, SM(ASCP)CM.
Experts discuss strategies for effectively communicating the importance of COVID-19 vaccination, highlighting the challenges healthcare professionals face in getting individuals to understand and act on recommendations. The speakers emphasize the prevalence of misinformation and the need for accurate science communication. One of the speakers shares his approach to engaging the public through storytelling and translational communication, rather than bombarding them with research data.
The conversation touches on the significance of vaccinations for various diseases, including COVID-19, flu, and RSV (respiratory syncytial virus), emphasizing the abundance of scientific data supporting their efficacy. The speakers stress the importance of positive and direct communication, sharing personal experiences of vaccination within family and community. The goal is to encourage conversations and address concerns, recognizing that people may have questions influenced by information on social media.
The discussion also delves into the practice of administering multiple vaccines simultaneously, with a focus on the safety of co-administering COVID-19 vaccines with live attenuated vaccines like MMR (measles, mumps, rubella) or varicella. The speakers mention a study highlighting adults' preference for single vaccines at a time, contrasting with the common practice in pediatrics. They reassure the public about the safety of combining vaccines and encourage consulting healthcare practitioners for personalized advice.
The conversation concludes with a brief mention of the Novavax COVID-19 vaccine's limitations in individuals under 12 years old, attributing this to the lack of extensive studies in younger children. The speakers emphasize the ongoing commitment to research and safety considerations, addressing potential concerns about vaccine adjuvants and encouraging public understanding through continued communication and dialogue with healthcare professionals.
Video synopsis is AI-generated and reviewed by PatientCare editorial staff.